clinical trial · NCT07128550
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
Viral HepatitisTobevibartElebsiranBulevirtide
brief summary
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide
started
Jul 30, 2025
primary completion
Dec 1, 2026
completion
Jul 1, 2031
last updated
Mar 31, 2026
official title
A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (ECLIPSE 2)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol